

Haijun Zhong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9764542/publications.pdf>

Version: 2024-02-01

10
papers

48
citations

2258059

3
h-index

2053705

5
g-index

10
all docs

10
docs citations

10
times ranked

18
citing authors

#	ARTICLE	IF	CITATIONS
1	First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2022, 40, 3021-3021.	1.6	0
2	Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.. Journal of Clinical Oncology, 2022, 40, LBA4011-LBA4011.	1.6	18
3	CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.. Journal of Clinical Oncology, 2022, 40, 3574-3574.	1.6	0
4	Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.. Journal of Clinical Oncology, 2021, 39, 2566-2566.	1.6	11
5	Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital. Frontiers in Pharmacology, 2021, 12, 632076.	3.5	3
6	Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.. Journal of Clinical Oncology, 2021, 39, e16037-e16037.	1.6	0
7	Safety and efficacy of apatinib as third or later line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma: A post-marketing phase IV study.. Journal of Clinical Oncology, 2021, 39, e16034-e16034.	1.6	0
8	Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.. Journal of Clinical Oncology, 2021, 39, e14547-e14547.	1.6	1
9	PDZ Binding Kinase/T-LAK Cell-Derived Protein Kinase Plays an Oncogenic Role and Promotes Immune Escape in Human Tumors. Journal of Oncology, 2021, 2021, 1-16.	1.3	4
10	HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. , 2020, 8, e001279.		11